Form 4: Inspire Medical Officer Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Inspire Medical Systems' Chief Product and Innovation Officer, John Rondoni, sold 109 shares of common stock for $100 per share under a pre-arranged trading plan.
Summary
- John Rondoni, Chief Product and Innovation Officer at Inspire Medical Systems, Inc. (INSP), reported a sale of common stock.
- The transaction involved the disposition of 109 shares of common stock.
- The shares were sold at a price of $100 per share.
- The sale occurred on January 9, 2026.
- Following this transaction, John Rondoni beneficially owns 13,797 shares of common stock directly.
- The sale was executed pursuant to a Rule 10b5-1 trading plan established on May 28, 2025.
- The reported beneficial ownership includes 140 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan since the previous Form 4 filing on May 21, 2025.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale executed under a pre-arranged Rule 10b5-1 trading plan. This type of transaction is generally considered neutral as it is scheduled in advance and does not necessarily reflect new sentiment about the company's immediate prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing details a routine insider transaction for an executive at Inspire Medical Systems, a company operating in the medical device sector, specifically known for its sleep apnea solutions. Such transactions are common and typically do not reflect broader industry trends unless they are unusually large or frequent, which is not indicated here.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Adherence | The reported sale transaction was executed pursuant to a Rule 10b5-1 trading plan dated May 28, 2025, indicating adherence to pre-arranged trading policies designed to avoid insider trading allegations. | 2025-05-28 | Enhances transparency and reduces potential for insider trading concerns by pre-scheduling trades, aligning with best practices in corporate governance. |
Stakeholder Impact
- Shareholders: The sale represents a minor reduction in an executive's direct holdings, which is a routine event and unlikely to have a significant impact on shareholder confidence or the company's valuation, especially given it was pre-planned.
Key Dates
| Date | Description |
|---|---|
| 2025-05-21 | Date of Reporting Person's previous Form 4 filing. |
| 2025-05-28 | Date the Rule 10b5-1 trading plan was established. |
| 2026-01-09 | Date of the reported transaction (sale of common stock). |
| 2026-01-12 | Signature date of the Form 4 filing. |
Keywords
Inspire Medical Systems, INSP, Insider Trading, Form 4, Stock Sale, John Rondoni, 10b5-1 Plan, Medical Devices, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.